Cambridge, MA – Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks ...
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...
BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results